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Abstract: Stroke is one of the leading causes of death and adult disability in the world.
Although many molecules have been documented to have a neuroprotective effect, the majority
of these molecules failed to improve the neurological outcomes for patients with brain ischemia.
It has been proposed that neuroprotection alone may, in fact, not be adequate for improving the
prognosis of ischemic stroke. Neuroprotectants that can regulate other processes which occur in
the brain during ischemia could potentially be targets for the development of effective therapeutic
interventions in stroke. Neuronal Per-Arnt-Sim domain protein 4 (Npas4) is an activity-dependent
transcription factor whose expression is induced in various brain insults, including cerebral
ischemia. It has been shown that Npas4 plays an important role in protecting neurons against
many types of neurodegenerative insult. Recently, it was demonstrated that Npas4 indeed has a
neuroprotective role in ischemic stroke and that Npas4 might be involved in modulating the cell
death pathway and inflammatory response. In this review, we summarize the current knowledge
of the roles that Npas4 may play in neuroinflammation and ischemia. Understanding how ischemic
lesion size in stroke may be reduced through modulation of Npas4-dependent apoptotic and
inflammatory pathways could lead to the development of new stroke therapies.
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1. Introduction
Stroke is the second leading single cause of death and the most common cause of long-term
disability in the adult population worldwide [1]. Ischemic stroke is more prevalent than that of
hemorrhagic stroke, accounting for approximately 87% of all strokes [2]. Cerebral ischemia occurs
as a result of sudden impairment of local cerebral blood flow, leading to irreversible brain tissue
damage within an area known as the infarct core. This unsalvageable region is surrounded by
the penumbra, a rim of moderately ischemic tissue (due to blood flow from collateral vessels) that
is at risk of infarction. As the penumbral tissue is functionally impaired but structurally intact
and viable, damage to neurons within the ischemic penumbra is potentially salvageable by means
of reperfusion or therapeutic effort [3]. If left without intervention, the penumbral tissue will be
recruited gradually to the infarct core, which will expand with time into a maximal volume, and also
become irreversibly damaged.
Npas4, which also has a number of other synonyms such as neuronal transcription factor
(Nxf) [4,5] and limbic-enriched PAS domain protein (LE-PAS) [6], is an activity-dependent
transcription factor belonging to the basic Helix-Loop-Helix (bHLH)-PAS protein family. Npas4 has
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been demonstrated to play a role in regulating both inhibitory and excitatory synapse formation in a
neuronal cell type-specific manner [7–9] and controlling the expression of brain-derived neurotrophic
factor (BDNF) [7,10], a neurotrophin that is important for neuronal survival, differentiation
and synaptic plasticity [11,12]. Studies have also revealed a functional role for Npas4 in
hippocampus- [13,14] and amygdala-dependent [15] learning and memory formation, as well as
cognitive and social neurobehavior [16]. Due to its central role in homeostasis of neuronal
excitation and inhibition, Npas4 has been implicated in a host of psychiatric conditions such
as bipolar disorder [17], autism spectrum disorder [18] and cognition-related disorders [19,20].
More importantly, upregulated Npas4 expression has been reported in various brain insults,
including focal and global ischemic stroke [4,21–24].
Previously, although not in the context of ischemic damage, it has been shown that Npas4
plays a critical role in protecting neurons against neurodegenerative insults [23–25]. Recently, our
laboratory has demonstrated that Npas4 indeed has a neuroprotective role in ischemic stroke and
that Npas4 might be involved in modulating the post-stroke inflammatory response [26]. This review
summarizes the current knowledge of the roles that Npas4 may play in stroke and describes the
possible cellular and molecular mechanisms by which Npas4 links the neuroinflammatory and
ischemic processes.
2. Npas4 Is a Member of the Basic Helix-Loop-Helix (bHLH)-PAS Transcription Factor Family
2.1. The bHLH-PAS Family of Transcriptional Regulators
The bHLH-PAS proteins are members of the bHLH superfamily of transcription factors that
generally contain two structurally conserved PAS domains [27]. Studies have shown that bHLH-PAS
proteins are involved in many biological processes such as the physiological responses to hypoxia,
metabolism of xenobiotics and central nervous system (CNS) development [28]. For example,
hypoxia-inducible factor 1 alpha (Hif-1α), the first identified member of the Hif family, has
been shown to promote angiogenesis and erythropoiesis by inducing erythropoietin and vascular
endothelial growth factor (VEGF) under hypoxic conditions [29]. Mice deficient in Hif-1α die in utero
by embryonic Day 10 due to abnormal vascularization [30]. Aryl hydrocarbon receptor (Ahr), one
of the best characterized bHLH-PAS proteins, has been demonstrated to respond to environmental
pollutants by initiating transcription of xenobiotic response genes [31], while murine single-minded
1 (Sim1), the mammalian homolog of the Drosophila Sim protein, has been determined to play a role
in CNS development, specifically the development of the hypothalamic-pituitary axis [32].
The bHLH-PAS factors are not active individually but function as homo- or heterodimers
and thus, they can be subdivided into two classes according to their partnering behavior. Class I
bHLH-PAS factors, which include Ahr, the Hif family (Hif-1α, Hif-2α and Hif-3α) and the Sim
proteins (Sim1 and Sim2), neither homodimerize nor heterodimerize with other members of the
Class I family. To form transcriptionally active complexes, Class I factors must dimerize with Class II
bHLH-PAS factors, which promiscuously heterodimerize with other Class I factors and are also able
to form homodimers. The best studied Class II protein is the ubiquitous aryl hydrocarbon receptor
nuclear translocator (Arnt) which is the most common dimerization partner for both the Ahr and Hif
proteins. Other members of the Class II family include the tissue-restricted Arnt2 and the circadian
rhythm proteins brain and muscle Arnt-like 1 (Bmal1) and Bmal2 [28,33]. In general, a functional
bHLH-PAS transcriptional complex is formed when a Class I factor dimerizes with its respective
partner protein from Class II. The choice of partner protein determines the DNA binding specificity
of the dimer for target gene regulatory elements.
By definition, members of the bHLH-PAS family contain several highly conserved domains and
thus, they also share a common domain organization. The N-terminal half of these proteins contains
a bHLH domain which is used in dimerization with other bHLH-PAS proteins and also forms part
of the DNA-binding interface of the resulting dimer [34]. Adjacent to the bHLH domain is the
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PAS homology domain consisting of two repeats, termed PAS A and PAS B, which are separated
by a spacer region of variable length [35]. PAS domains are not confined to the DNA-binding
bHLH transcriptional regulators but are found in more than 200 proteins, where they act as sensor
domains that respond to diverse stimuli such as oxygen, light, small ligands, and redox potential [36].
When present in bHLH-PAS proteins, the PAS domains determine partner choice and prevent
dimerization with inappropriate members of the bHLH-PAS family [33]. In addition to contributing
to dimerization specificity, they also confer dimer stability [37] and subsequently, have been shown to
have a role in DNA binding [33]. Npas4 is the newest member of the bHLH-PAS family of regulatory
proteins [4–6]. It is so called because of its expression pattern, which is largely restricted to neurons
of the brain, and because it contains a conserved PAS domain.
2.2. Structure of the Mouse Npas4 Gene and Its Transcript
In the mouse genome, the Npas4 gene is located on the reverse strand of chromosome 19A and
spans a region of approximately 5.6 kilobases (kb) (Figure 1A). The human NPAS4 gene is mapped
to chromosome 11q13 and its sequence is well conserved among mammals [5]. The total length of
the primary mouse Npas4 transcript is approximately 3277 base pairs (bp) and it consists of a 2409 bp
coding region which is flanked by untranslated regions (UTRs) of 155 bp at the 5’ end and 713 bp
at the 3’ end. The predicted molecular mass of the mouse Npas4 protein is 87.4 kilodalton (kDa),
though in vitro transcription and translation of a complementary DNA (cDNA) sequence coding for
the full-length mouse Npas4 protein produced a protein of approximately 110 kDa [6].
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sequence of the Npas4 protein has a low degree of homology to other bHLH-PAS factors. Indeed, it
shares only 24% overall amino acid identity with Sim2, the protein with which it shares the highest
degree of homology [5].
2.4. Npas4 and Its Interaction with Other bHLH-PAS Factors
Using a mammalian two-hybrid system, Ooe et al., demonstrated that the NPAS4 protein formed
heterodimer complexes with several Class II bHLH-PAS family members, namely ARNT, ARNT2 and
BMAL1, but not with BMAL2. Of these proteins, NPAS4’s preferred binding partner is ARNT2 whose
expression is known to be abundant and restricted to the brain [38]. In addition, NPAS4 did not
homodimerize or heterodimerize with Class I factors such as SIM2 and circadian locomotor output
cycles kaput (CLOCK) [5], suggesting that it belongs to Class I of the bHLH-PAS family. A subsequent
study by the same group verified these data in vivo using a co-immunoprecipitation assay of whole
brain extracts to show that the ARNT proteins are the preferred dimerization partners of NPAS4.
Although it was observed that the NPAS4 protein exhibited a stronger interaction with ARNT2
than ARNT, the reporter assay showed similar levels of transcriptional activity with NPAS4/ARNT
and NPAS4/ARNT2 complexes [24]. Furthermore, it has been shown that while both Npas4 and
Arnt mRNAs were detected in the striatum, no significant Arnt2 expression was observed [39].
Therefore, these data suggest that even though Npas4 has a greater affinity for Arnt2, in some regions
of the brain (such as the striatum), Arnt can form functional complexes with Npas4 and could play
an independent role in regulating Npas4 signaling in vivo.
3. Expression of Npas4
3.1. Npas4 Expression in Adult Tissues
Expression of bHLH-PAS factors varies from those that are ubiquitously expressed, such as
Arnt, to those whose expression is spatially restricted to specific tissues. Like the related bHLH-PAS
factor Sim2, Npas4 has a restricted expression pattern and is found in only a very small number of
tissues in the adult organism. Northern blot analysis of various rodent tissues revealed that Npas4
is primarily expressed in the brain where a major transcript of approximately 3.5 kb was detected,
though low level expression of additional transcripts (ranging from 4 to 6 kb) was also seen in the
testis [6,22,23]. The size of the transcript detected in brain samples corresponds to the expected size of
the mature Npas4 mRNA, however it is unclear whether the larger transcripts present in the testis are
true isoforms of Npas4. These observations suggest that Npas4, similar to Hif-1α and Bmal2 (which
have been shown to be encoded by different tissue-specific mRNA isoforms) [40,41], might undergo
alternative splicing in different tissues. In human, the NPAS4 transcript was mainly expressed in
brain tissue, though, unlike in rodents, no expression was observed in the testis [5]. This brain-specific
expression pattern seems to be conserved even in lower vertebrates as demonstrated by our recent
study which showed that, in the adult zebrafish, the expression of the zebrafish Npas4 homolog npas4a
was also restricted to the brain [42].
3.2. Enriched Npas4 Expression in the Limbic System of the Brain
In the resting state (i.e., a normal, unstimulated brain), Npas4 is expressed throughout the whole
brain at a low level, though it is enriched in certain regions such as the limbic system. The limbic
system is loosely defined, in both an anatomical and functional sense, as there is still some controversy
regarding precisely which brain structures comprise the limbic system and hence which aspects
of neurophysiology it regulates [43]. Most commonly, the limbic system refers to a collection of
subcortical structures, including the hippocampus, amygdala, fornix and cingulate gyrus, and it is
considered to be involved in learning and memory, regulation of emotion and emotional behavior,
sexual function and olfaction [44–46].
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Using immunohistochemical staining and in situ hybridization (ISH), it was shown that both
Npas4 transcript and protein are selectively expressed in the grey matter, but not in the white
matter [22]. Of all brain structures, Npas4 is most abundantly expressed in the hippocampus with the
highest expression being detected in the pyramidal cell layers of the cornu ammonis (CA1, CA2 and
CA3 regions) and the granule cell layer (GCL) of the dentate gyrus (DG) [4–6,22]. In addition, more
recent studies have also detected the expression of Npas4 protein in other limbic structures such as
the lateral nucleus of the amygdala and components of the basal ganglia, for example the nucleus
accumbens and ventral pallidum [15,21]. These observations indicate that Npas4 is a neuronal
transcription factor whose expression is enriched in the limbic system.
Brain structures outside of the limbic system that have lower levels of Npas4 expression include
the cortex, striatum, olfactory bulb (OB), cerebellum and hypothalamus [5,6,21,47,48]. In the cortex,
expression is highest in layers III and V and is present in the frontal, parietal and entorhinal
cortices [5,6,21,22]. Some species-specific differences in Npas4 expression have been observed in the
cerebellum; in the rat cerebellum, Npas4 expression is confined to the Purkinje cell layer, while in the
mouse cerebellum, Npas4 is expressed in both the GCL and the Purkinje cell layer [5,6].
3.3. Subcellular Localization of Npas4
As a member of the bHLH-PAS family of transcriptional regulators, Npas4 is expected to
be localized in the nucleus. This hypothesis was confirmed by an in vitro experiment whereby a
green fluorescent protein (GFP) construct containing the Npas4-coding region was transfected into
the COS-7 monkey kidney cells and the fluorescent GFP signal was detected within the nuclei of
the transfected cells [6]. This result was in line with the bioinformatic analysis in the same study
which predicted a nuclear localization for the Npas4 protein. In addition to the nucleus, it has
been shown that the Npas4 protein can be found in other parts of the cell. In rat primary cortical
neurons, endogenous Npas4 protein was detected by immunofluorescence in the soma, neurites and
also at synapses where it co-localized with the synaptic marker synaptophysin. These data suggest
that Npas4 could act as a dendritic transcription factor modulating neuronal activity and might be
involved in synaptic plasticity in the brain [22].
3.4. Cellular Distribution of Npas4
It has been stated that Npas4 is predominantly expressed in excitatory neurons [7],
though subsequent studies have revealed that Npas4 can also be detected in γ-aminobutyric
acid (GABA)ergic inhibitory medium spiny neurons in the limbic striatum [21], somatostatin
(SST)-expressing interneurons in the medial ganglionic eminence (MGE) at embryonic day 14 (E14) [9]
and newborn OB interneurons [49]. Interestingly, there is also evidence that Npas4 is expressed by
cells other than neurons. Using immunostaining, Yun et al., reported that, in the subgranular zone
(SGZ) of the DG, a small number of Npas4-expressing cells were also found to express markers of
neural progenitor cells (NPCs) such as SRY (sex determining region Y)-box 2 (Sox2) and doublecortin
(Dcx) [14]. In line with this, using two independent in vitro models of neurogenesis, our laboratory
has found that while Npas4 is not expressed in undifferentiated embryonic stem cells, it becomes
transiently upregulated at a stage that is characterized by proliferation of NPCs [50].
4. Regulation of Npas4 Expression by Neuronal Activity
4.1. Activity-Dependent Regulation of Npas4 Expression in Neurons
Neuronal activity can be defined as the propagation of a signal from one neuron to another.
Such signals are transmitted in the form of neurotransmitter molecules, which are generally described
as “excitatory” (such as glutamate) or “inhibitory” (such as GABA), where they bind to specific
receptors present on the membrane of the postsynaptic cell and trigger a cascade of events that
subsequently lead to the generation of an action potential or changes in the gene expression
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profile [51–53]. Although there are many types of stimuli that can induce Npas4 expression,
the primary signal for inducing the expression of Npas4 is an increase in nuclear calcium (Ca2+)
concentration that, in neurons, is largely regulated by excitatory neuronal activity.
Npas4 expression is rapidly induced (with a peak at approximately 1 h) in response to neuronal
activity, characteristic of the group of immediate early genes (IEGs) [7,54,55]. However, this induction
is transient as both Npas4 mRNA and protein have been shown to return to basal levels within
2 to 4 h following peak expression [7,55]. This activity-dependent induction of Npas4 has been
demonstrated both in vitro and in vivo by a number of different methods of stimulating excitatory
synaptic activity such as the use of glutamate, which resulted in global activation of glutamate
receptors (GluRs) [55] or the use of glutamate analogs N-methyl-D-aspartic acid (NMDA) [56,57]
and kainate [24], which selectively activate specific GluR subtypes. Predictably, this upregulation of
Npas4 expression was inhibited by the treatment with various GluR antagonists such as MK-801 [55],
R-2-amino-5-phosphonopentanoate (APV) [56] or 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) [7],
suggesting that these ligand-gated ion channels play an essential role in Npas4 signaling.
Recently, it was reported that the formation of neuronal activity-induced DNA double strand
breaks (DSBs) in the promoter of Npas4 was required for its expression [58]. Cultured primary
cortical neurons incubated with etoposide, a topoisomerase II (Topo II) inhibitor that causes DNA
DSBs [59], for 6 h resulted in an upregulation of 12 neuronal activity-dependent genes, including
Npas4. Further analysis suggested that this activity-dependent formation of DSBs is likely to be
mediated by Topo IIβ as knockdown of Topo IIβ attenuated both DSB formation and Npas4 expression
in response to neuronal stimulation [58].
4.2. Nuclear Ca2+ Signaling and Regulation of Npas4 Expression
More specifically, it was revealed that the activation of GluRs per se is not the determining
factor for Npas4 induction but rather the increase in nuclear Ca2+ that is a direct consequence of
neuronal activity and membrane depolarization. For example, it was demonstrated that Npas4
expression induced by the GABA receptor antagonist bicuculline could be abolished by pretreatment
with the Ca2+ chelator ethylene glycol tetraacetic acid (EGTA) [7]. Even treatment with potassium
chloride (KCl) to induce membrane depolarization (without activating GluRs) was demonstrated
to stimulate the expression of Npas4 both in vitro [7] and in vivo [23]. Indeed, Npas4 upregulation
was observed even in the absence of neuronal activity or membrane depolarization by treating
cells with thapsigargin, an inhibitor of the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA)
transporter which pumps cytosolic Ca2+ into the endoplasmic reticulum. The resultant increase in
cytosolic Ca2+ concentration was able to induce Npas4 expression which peaked at 30 min before
subsequently declining to baseline levels by 4 h [24]. Finally, inhibition of nuclear Ca2+ signaling
with calmodulin (CaM) binding-peptide (CaMBP4), a nuclear protein that binds to and inactivates
the nuclear Ca2+/CaM complex, was demonstrated to prevent the induction of Npas4 [25].
The exact nature of the molecular events downstream of nuclear Ca2+ signaling that lead
to Npas4 upregulation are not completely understood, though a number of recent advances are
beginning to shed light on the matter. The induction of Npas4 was also found to be partially
reliant on Ca2+/CaM-dependent protein kinase type IV (CaMKIV) function [25], suggesting that
there may be targets of CaMKIV that regulate Npas4 transcription. One possible candidate is the
cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB), a Ca2+-sensitive
target of CaMKIV, however the likelihood that the transcription of Npas4 is regulated by CREB seems
improbable given that the promoter region of the Npas4 gene does not contain any cAMP response
element (CRE) sites [25]. On the other hand, there are several downstream regulatory element (DRE)
sites present in the Npas4 proximal promoter, making it likely that Npas4 expression is under the
control of DRE-antagonist modulator (DREAM), a transcriptional repressor which is released from
DNA upon binding of Ca2+ [60]. Indeed, using a chromatin immunoprecipitation (ChIP) assay, it was
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shown that DREAM bound directly to the Npas4 promoter and that treatment of neurons with KCl
resulted in the Ca2+-dependent unbinding of DREAM from the promoter [61].
Given that Ca2+ is a ubiquitous second messenger present in all cell types, one might ask what
are the factors that drive neuron-specific expression of Npas4? The answer to this question probably
lies within the promoter and intron I of Npas4 gene where putative RE1-silencing transcription
factor (REST) binding sites were recently identified using comparative genomics [62]. REST is a
transcriptional repressor that is primarily expressed in non-neuronal cells where it silences expression
of neuronal genes [63]. Using a reporter assay, it was shown that REST indeed was able to repress
Npas4 transcription in embryonic stem cells, indicating that Npas4 expression is negatively regulated
by REST in non-neuronal cells [64].
5. Npas4 Expression in Response to Cerebral Ischemia
Cerebral ischemia is a condition in which blood flow to the brain is not sufficient to meet
metabolic demand. This rapidly leads to energy depletion within neurons as adenosine triphosphate
(ATP) production by oxidative phosphorylation ceases. Without energy, ATP-dependent ion pumps
and neurotransmitter transporters fail which leads to loss of membrane potential and uncontrolled
glutamate release into the extracellular space [65]. Both of these events trigger repetitive peri-infarct
depolarization of neurons within the penumbra leading to increased levels of intracellular Ca2+ and
induction of activity-regulated genes such as Npas4. Ischemic gene expression can activate both cell
survival programs and pathogenic cascades, including pro-inflammatory, apoptotic and/or necrotic
pathways [66].
A microarray study of gene expression following stroke showed that Npas4 was one of the most
profoundly upregulated genes in the rat brain following 2 h of middle cerebral artery occlusion
(MCAo). Temporal profiling revealed that Npas4 mRNA induction exhibited a biphasic pattern, with
an early upregulation at 0.75 h of reperfusion before decreasing to baseline levels between 3 to 6 h and
a subsequent transient induction at 12 h before once more returning to basal levels. Using ISH, it was
shown that the Npas4 transcript was elevated throughout the entire challenged hemisphere in both
the ischemic core and penumbra, with no change being observed in the contralateral (unchallenged)
hemisphere. In the peri-infarct regions, such as cingulate cortex and medial striatum, Npas4 mRNA
induction was high but transient and the transcript returned to control levels after 3 h of reperfusion.
On the other hand, the induction of Npas4 in the ischemic core was moderate but persisted for a
period of up to 12 h after reperfusion. Analysis of Npas4 protein expression after focal ischemia using
Western blot has shown that no upregulation of Npas4 was detected beyond 3 h of reperfusion [22].
Our laboratory has shown that there was a robust but transient induction of Npas4 protein that
peaked 1.5 h following the induction of stroke before progressively declining to baseline levels by
12 h post-stroke. In addition, this stroke-induced upregulation of Npas4 was found not only in the
ischemic penumbra but also detected in brain regions outside of the penumbra, more specifically in
the corticolimbic system that is critically linked to emotion and cognition [21]. Recently, using oxygen
and glucose deprivation (OGD) as an in vitro model of ischemia, we also found that Npas4 transcript
levels were upregulated in primary mouse cortical neurons [26].
Global cerebral ischemia, caused by clamping of the common carotid arteries for 10 min,
produced a much more sustained response in Npas4 mRNA expression. Upregulation of Npas4 was
most evident in the hippocampus where increased expression was observed for up to 24 h after
reperfusion [22]. Furthermore, the increase in Npas4 expression was directly correlated with the
duration of the ischemic insult and hence, the severity of neuronal damage [22]. Expression of Npas4
protein was detected in surviving cells within the CA1 and CA2 regions of the rat hippocampus
10 days after transient global cerebral ischemia [24] and likewise, in the cortex and hippocampus
(CA1 and CA3 regions) after chronic global ischemia [55].
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6. Functions of Npas4 Following Ischemic Brain Injury
6.1. Neuroprotection
It is well established that neuronal survival is dependent on physiological levels of
synaptic activity as blockade of normal excitation in vitro or in vivo causes cell death [67,68].
Activity-dependent neuroprotection is induced by Ca2+ entry specifically through synaptic NMDA
receptors (NMDARs) [57] and requires the propagation of Ca2+ transients to the nucleus [52,69,70].
Interestingly, Npas4 expression has also been shown to be induced specifically by activation of
synaptic, but not extrasynaptic, NMDARs [57]. More importantly, there is increasing evidence which
suggests that Npas4 also has a role in this activity-dependent neuroprotective response.
The neuroprotective effect of Npas4 has been demonstrated in various animal models of acute
neurological injury. Using a rat model of seizure, Zhang et al., showed that dorsal hippocampal
neurons transduced to express Npas4 using an adeno-associated virus (AAV) vector were protected
against kainic acid (KA)-induced cell death with a 92% inhibition of cell death compared to the
non-injected side (contralateral). Conversely, widespread KA-induced neuronal cell death was
observed in animals injected with negative control vectors (i.e., LacZ and Empty), suggesting that
Npas4 protects against seizure-induced cell death [25]. Using a different approach, Ooe et al.,
generated a knockout mouse model for Npas4 to understand its functions in vivo. They were able
to show that Npas4 knockout (Npas4´{´) mice were morphologically indistinguishable from their
wild-type littermates, with no growth retardation and no significant abnormality. However, they had
a shorter lifespan and by 16 months, only about 20% to 30% of Npas4´{´ mice survived while almost
all wild-type mice survived. Intriguingly, the brains of Npas4´{´ mice showed signs of cumulative
neurodegeneration such as a significant increase in glial fibrillary acidic protein (GFAP) expression
when compared with wild-type littermates [24], which is an indication of glial cell activation and thus
neuronal damage [71]. In addition, when challenged with a dose of kainate that was not fatal for the
wild-type littermates, three out of eight Npas4´{´ mice died within five days and the remaining mice
exhibited serious abnormal behavior and severe brain damage [24].
Npas4 has also been linked to the neuroprotective phenomenon of preconditioning.
Cortical spreading depression (CSD), which is characterized by slowly propagating waves of
depolarizing activity, is a form of pre-ischemic conditioning that has been shown to mediate
neuroprotection against subsequent cerebral ischemia [72,73]. Interestingly, it has been shown that
both Npas4 mRNA and protein were transiently induced in neuronal cells following CSD [23].
Further analysis demonstrated that Npas4 was necessary for the protective effect of CSD since
F-11 cells (a fusion product of embryonic rat dorsal root ganglion (DRG) cells with a mouse
neuroblastoma cell line N18TG-2) treated with RNA interference (RNAi) against Npas4 were shown
to be more susceptible to potassium cyanide (KCN)-induced cell death [23]. In a similar study,
pretreatment of mouse hippocampal neurons with bicuculline for a period of 12 to 16 h was shown
to reduce the percentage of cells that underwent apoptosis following withdrawal of growth factors or
treatment with the apoptosis-inducing agent staurosporine. Importantly, the neuroprotective effect
of bicuculline pretreatment was abolished when neurons were infected with an Npas4-RNAi AAV
construct [25].
Recently, the neuroprotective role of Npas4 has also been extended to ischemic damage.
Using OGD, our laboratory has demonstrated that the knockdown of Npas4 in cultured neurons
resulted in increased susceptibility to cell death as demonstrated by the increased propidium iodide
membrane permeability. The protective effect of Npas4 was further investigated in vivo using a
photochemically-induced stroke model in mice. We found a significantly larger lesion size and
increased neurodegeneration in Npas4´{´ mice when compared with wild-type mice following the
induction of cerebral ischemia, confirming that Npas4 is neuroprotective in ischemic stroke [26].
The central role of BDNF in neuronal survival is well documented [74–76] and there is some
evidence that Npas4 regulates the activity-dependent transcription of BDNF. In a DNA microarray
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experiment performed in E16 mouse hippocampal neurons, it was shown that BDNF expression was
reduced by approximately two-fold in primary neuron cultures with knockdown of Npas4 expression
using RNAi. Moreover, cultured neurons from mice deficient in Npas4 exhibited a reduction in
KCl-induced BDNF mRNA expression as compared to wild-type controls. Using a ChIP assay, the
Npas4 protein was shown to bind to BDNF promoters I and IV with approximately equal affinity, but
not to the coding region or 31 UTR, in primary rat cortical cultures treated with KCl [7]. A similar
result was reproduced in a non-neuronal human cell line; when both NPAS4 and ARNT2 were
co-transfected into HEK 293 cells, the subsequent ChIP experiment demonstrated that NPAS4-ARNT2
dimer was enriched relatively more on human BDNF promoter I than on promoter IV [10].
6.2. Apoptosis
Surprisingly, while it was shown that Npas4 expression enhances cell survival and is
neuroprotective [23–26], Hester et al., reported that AAV-mediated overexpression of Npas4 in
cultured cells led to a decrease in cell viability over several days of culture compared to cells
infected with a control vector expressing GFP. More specifically, this loss of viability was lessened by
removal of the Npas4 C-terminal TAD, suggesting that Npas4-dependent transcriptional activity is
essential for the observed cytotoxic effect. Using microarray analysis with HeLa cells overexpressing
Npas4, it was shown that the pro-apoptotic gene Bax was upregulated and this result was confirmed
by Western blot analysis, where a significant increase of Bax protein expression was observed.
Subsequently, a ChIP assay was used to demonstrate that the endogenous BAX promoter was bound
by Npas4 when both Npas4 and Arnt2 were overexpressed in HeLa cells [23]. In line with this study,
our laboratory has also revealed that Npas4 plays a role in modulating apoptosis. Npas4´{´ mice
subjected to focal cerebral ischemia showed a significant decrease in the number of apoptotic cells
in the lesion core as compared to wild-type mice as seen by a reduction in both TUNEL staining
and the number of cells expressing apoptosis-inducing factor (AIF) [26]. Since the total number of
degenerating cells at the lesion site was in fact increased in Npas4´{´ mice, we hypothesize that a
switch from apoptosis to necrosis may explain this observation as it has been shown that blockade of
a specific cell death mechanism does not preclude cell destruction but instead promotes an alternative
pathway [77]. It is known that a switch from apoptotic to necrotic cell death is detrimental as the latter
is always a pathological process that augments inflammation whereas the former induces anergy or
an immunosuppressive phenotype [78]. Therefore, such a switch may also account for the larger
lesion size seen in Npas4´{´ animals. These findings suggest that one of the protective effects of
Npas4 is to limit tissue damage through modulation of the cell death pathway by directing damaged
cells to undergo apoptosis instead of necrosis.
6.3. Neuroinflammation
In the brain, neuroinflammation is an important defense mechanism that helps to protect the
CNS. On the other hand, uncontrolled or extended neuroinflammation is harmful and can induce
rapid neuronal death in the ischemic core which progressively expands toward the penumbral
area [79]. Interestingly, our laboratory has also shown that Npas4 deficiency resulted in a significant
increase in the number of activated microglia and astrocytes 96 h after the induction of stroke [26].
Microglia are the resident macrophages of the CNS [80] and function as scavenger cells in the
event of brain injury [81]. Following activation by ischemia, microglia can undergo morphological
transformation into phagocytes capable of releasing a variety of cytotoxic and/or cytoprotective
substances [82].
Although it is unclear whether microglial activation is necessarily destructive following ischemic
stroke, there is a considerable amount of data suggesting a role for activated microglia in worsening
brain injury. Treatment with edaravone, a potent free radical scavenger, after focal ischemia led to a
marked reduction of brain infarct size and improvement of neurological recovery in mice by reducing
microglial activation [83]. Using a rat model of permanent MCAo, Gunther et al. demonstrated
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that repetitive hyperbaric oxygen treatment-induced suppression of microglial activation was able to
reduce the infarct volume [84]. Direct evidence has also been presented to support a damaging role
of microglia on neuronal cells following ischemic insults when increased neuronal loss was observed
in the presence of microglia [85,86]. Conversely, some studies have reported that microglia or their
secreted products may in fact protect cells. The protective effects of microglia have been shown to
be mediated by their ability to phagocytose infiltrating neutrophils, which are known to secrete free
radicals and other inflammatory mediators, and through the elimination of excitotoxins from the
extracellular space after stroke [87]. In addition, it has been shown that microglia can synthesize
and release several compounds, such as growth factors and neurotrophins, that promote neuronal
survival and brain tissue repair in the event of brain injury [88,89].
It is well known that astrocytes carry out a variety of functions, including scavenging free
radicals, prevention of excitotoxicity and maintenance of ionic homeostasis, which are critical for
normal brain development and function [90]. After brain ischemia, astrocytes are activated resulting
in increased production of intermediate filament proteins, such as vimentin and GFAP, and a
phenomenon termed reactive astrogliosis occurs, which is characterized by profound morphological
and functional changes in astrocytes [91]. It has been demonstrated that astrocytes, like microglia,
also participate in post-ischemic brain inflammation by secreting cytokines and inducible nitric
oxide synthase (iNOS), as well as factors that can induce additional microglial activation [92].
Astrocytes, together with neurons and endothelial cells, also produce tumor necrosis factor-like
weak inducer of apoptosis (TWEAK) that, by interacting with Fn14 receptors present on astrocytes,
can stimulate the production of pro-inflammatory molecules [93,94]. Intriguingly, it has been
reported that the expression of TWEAK and Fn14 were elevated in a murine stroke model and
that intracerebroventricular injection of a soluble decoy (osteoprotegrin (OPG)-Fc protein) to Fn14
significantly reduced the infarct size [94].
Upregulated cytokine expression in the brain has been documented after a variety of insults such
as stroke. In addition to being expressed by the immune cells, cytokines are also produced by resident
brain cells, including neurons and glial cells [95]. In ischemic brain injury, interleukin (IL)-6 and
tumor necrosis factor alpha (TNF-α) are largely thought to act as pro-inflammatory cytokines which
exacerbate brain damage and are involved in the initiation of early inflammation [96]. We have noted
that Npas4´{´ mice had both increased IL-6 and TNF-α expression post-stroke [26]. Remarkably, it
has been documented that IL-6 also has an anti-apoptotic function after focal ischemia [97]. Given the
fact that we have shown that Npas4 is involved in the caspase-independent apoptotic pathway and
that other studies have demonstrated that TNF-α can induce necrosis in cells that failed to activate the
pro-survival signaling cascades and apoptosis [98], we hypothesize that the switch from apoptosis to
necrosis is responsible for the aggravated brain injury observed in mice lacking Npas4.
Several Npas4 target genes have also been implicated in the inflammatory response.
For example, the IEG transcription factor c-Fos, whose expression is regulated by Npas4 [13],
belongs to the Fos family of proteins that dimerize with c-Jun to form the activator protein
1 (AP-1) transcription complex [99,100]. Studies have shown that c-Fos plays critical roles in
the molecular mechanisms underlying a number of cellular processes, including proliferation,
differentiation and apoptosis [101,102]. Interestingly, it has been reported that c-Fos also
functions as an anti-inflammatory transcription factor by suppressing the activation of nuclear
factor (NF)-κB [103], a transcription factor that regulates the expression of TNF-α and other
pro-inflammatory cytokines [104]. Furthermore, a recently identified Npas4 target gene murine
double minute 2 (MDM2), an E3 ubiquitin ligase which was upregulated in Npas4´{´ OB granule
cells [49], has been shown to act as a co-factor for NF-κB at target gene promoters [105]. These findings
further support a role for Npas4 in inflammation.
An increasing number of studies have shown that M1/M2 polarization of microglia plays
a crucial role in the balance of inflammation [106]. Classically activated microglia (M1
phenotype) are cytotoxic due to the production of reactive oxygen/nitrogen species (ROS/RNS)
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and pro-inflammatory cytokines that contribute to the inflammatory response and propagation
of cell death beyond the initial ischemic region. In contrast, alternatively activated microglia
(M2 phenotype) block pro-inflammatory responses by expressing cytokines and receptors that are
involved in the inhibition of inflammation and restoration of homeostasis [107]. Given the fact that
it has been demonstrated that a microenvironment dominated by pro-inflammatory cytokines favors
polarization to M1 microglia and prevents an M2 switch [108] and that ablation of Npas4 resulted
in increased IL-6 and TNF-α cytokine levels in the brain following ischemia [26], it is possible that
microglia could be primed toward the M1 state in Npas4´{´ mice which maybe the underlying cause
of the increased stroke-induced brain injury and inflammation observed in these animals.
7. Conclusions
Npas4 is an activity-dependent transcription factor whose expression is robustly and transiently
upregulated in the brain during the acute phase of ischemia [21,22]. Although previous studies
have demonstrated a role for Npas4 in the protection of neurons against neurodegenerative insults,
we recently showed the neuroprotective effect of Npas4 in the context of ischemic damage as
Npas4 deficiency increased the susceptibility of cultured neurons to OGD-induced cell death and
exacerbated the severity of brain injury after focal ischemia in mice [26]. Stroke is one of the leading
causes of death and adult disability worldwide. While preclinical studies have demonstrated many
molecules as potential neuroprotective factors, the large majority of these molecules were unable to
reverse the neurological deficits in ischemic stroke patients [109]. This suggests that factors with
a neuroprotective effect alone are not sufficient to improve the prognosis of cerebral ischemia and
that neuroprotectants that can regulate other processes which occur in the brain during stroke, such
as neuroinflammation and cell death, could potentially be targets for the development of effective
therapeutic interventions in stroke.
After stroke, an inflammatory response is initiated within a few hours and is characterized
by the activation of astrocytes and microglia, as well as the subsequent infiltration of
granulocytes (neutrophils) and monocytes/macrophages [110]. Neuroinflammation is one of
the key pathophysiological mechanisms contributing to the progression of brain damage caused
by ischemia [95] and inhibition of this response has been shown to decrease infarct size and
improve neurological function in animal stroke models [111,112]. Although many experimental
anti-inflammatory approaches have been developed and proven successful [113–115], attempts to
translate this into clinical application have been disappointing [116,117]. This is not surprising since
increasing evidence demonstrates that the inflammatory response not only aggravates secondary
brain damage in the acute stage of stroke but also beneficially contributes to brain tissue repairing
and remodeling after an ischemic event. Therefore, inhibiting inflammation could be detrimental and
worsen long-term functional consequences after cerebral ischemia [118,119].
We recently demonstrated for the first time that Npas4 may have the capacity to regulate
the brain’s inflammatory response to stroke since genetic ablation of Npas4 significantly increased
activated astrocyte and microglial cell numbers, pro-inflammatory cytokines IL-6 and TNF-α levels
and caused a switch from apoptotic to necrotic cell death in mice subjected to photochemical
stroke [26]. Apoptosis is a highly controlled and regulated form of cell death that is characterized
by nuclear condensation, cell shrinkage, membrane blebbing and DNA fragmentation, whereby a
cell dies without causing damage to neighboring cells [120]. In contrast, necrosis is a pathological
process that results in cellular swelling, disruption of ionic and internal homeostasis, plasma
membrane rupture and cell lysis. This swiftly leads to the release of intracellular contents
that can contribute to excessive inflammation, edema and collateral damage to the surrounding
cells [78]. Therefore, harnessing the multidimensional neuroprotective capacity of Npas4 could
limit progressive neurodegeneration and neuroinflammation (Figure 2), potentially providing new
strategies for the treatment of ischemic stroke.
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Figure 2. Model of Npas4 neuroprotective function following cerebral ischemia. Ischemic challenge 
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the cell death pathway such that damaged cells undergo apoptosis in preference to necrosis and (2) 
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